Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia.
D000328:Adult; D001374:Azacitidine / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D010710:Phosphates / Q000097:blood*; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D010710:Phosphates; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D013866:Thioguanine; D001374:Azacitidine; D011241:Prednisone; D003630:Daunorubicin